Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
Oxford Biomedica, a leading gene and cell therapy group, has signed a one-year clinical and commercial supply deal with AstraZeneca for a potential Covid-19 vaccine.
The agreement relates to the adenovirus vector-based vaccine candidate AZD1222, which entered clinical trials at multiple sites in the UK recently.
Oxford Biomedica is working with AstraZeneca and other manufacturing organisations to provide large scale manufacturing capacity for this vaccine candidate. AstraZeneca will have access to Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre, Oxbox.
At the beginning of April 2020, Oxford Biomedica joined a consortium including the Jenner Institute in relation to the potential for large scale manufacture of AZD1222. Subsequently, on 30th April 2020, AstraZeneca and Oxford University announced an agreement to enable global development, manufacturing and distribution of the vaccine.
John Dawson, Chief Executive Officer of Oxford Biomedica, commented:
“We are proud to be a part of the manufacturing consortium working with the Jenner Institute at University of Oxford, for the early manufacturing and scale up of this viral vector-based candidate for COVID-19. Following the recent announcement of an agreement between the University of Oxford and AstraZeneca, we are very pleased to be one of AstraZeneca’s global network of manufacturing partners, and look forward to them being the third company to have rapid access to our specialised manufacturing capacity for this vaccine candidate at Oxbox”.
Read more HERE.